· Investment Strategies · 1 source · Updated · Verified
Anew Labs $290M at $1.5B Is Reuters Sources — ByteDance Did Not Comment
Reuters reported on September 16, 2026 that ByteDance’s spun-off AI drug unit Anew Labs completed a $290 million inaugural external raise at $1.5 billion. Two people; ByteDance and the investors did not immediately comment. HSG, IDG Capital, and Hillhouse were named as leads; ByteDance retains 56%. HSG is not Sequoia Capital US.
By Venture Capital Tracker Editorial
Anew Labs’ $290 million raise at $1.5 billion is Reuters, two people, September 16, 2026 — not a company blog. ByteDance and the named investors did not immediately comment. Last verified September 16, 2026.
Unexpected truth: treat this as a reported inaugural external round inside a ByteDance-controlled vehicle. A second source told Reuters ByteDance keeps 56% after the fundraising. There is no series letter, no pre/post label, and no pipeline or revenue print in that item.
HSG is formerly Sequoia China. It is not Sequoia. Same disambiguation as Clipto.
Five-minute decision
| If you need… | Verdict |
|---|---|
| What happened | Reported close. $290M at $1.5B. Sep 16 Reuters. |
| Company confirmation | None in that story. |
| Control | ByteDance 56% after (second source). |
| Leads (sources) | HSG, IDG Capital, Hillhouse; 5Y Capital co-lead. |
| Series / ARR / assets | Unknown. |
/fund/ pages | None for the named China firms. |
Investigate further when: a company or investor statement lands, or you already diligence ByteDance healthcare as a separate P&L.
Wait or pass when: you need a primary release, a series letter, or US Sequoia on the cap table.
What Reuters printed
| Field | Detail |
|---|---|
| Company | Anew Labs; Shanghai; AI drug discovery (Reuters description) |
| Amount / mark | $290M · $1.5B · inaugural external |
| Structure | Spin-off from ByteDance so drug discovery can run on different “industry logic” (source) |
| Other names | Gaorong, Primavera, Boyu, SBP Group, Shanghai Future Industries Fund |
| IDG overlap on this site | PHYMI ~$100M seed — different deal |
No product metrics. No named molecules. No comment from the company. Confidence is reported.
Entity: Anew Labs. Day index: September 15–16.
Follow Venture Capital Tracker on Google
Add VCT as a preferred source to see more of our venture-capital reporting in Google Search.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
